Skip to content

Study · Animal study (in vivo) · rat · 2021

6 results

Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia.

Zemba Cilic A, Zemba M, Cilic M, Balenovic I, Strbe S, Ilic S, Vukojevic J, Zoricic Z, Filipcic I, Kokot A, Drmic D, Blagaic AB, Tvrdeic A, Seiwerth S, Sikiric P

Behavioural brain research18 Sept 2020Cited by 15 (Europe PMC)

PMID32956773 (opens in a new tab)DOI10.1016/j.bbr.2020.112919 (opens in a new tab)PepBankPUB-32956773
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, BPC‑157 (0.01 mg/kg intraperitoneally) given alone counteracted the acute motor-activity effects induced by amphetamine, apomorphine and MK-801.

    In plain wordsIn rats, BPC‑157 reduced the changes in movement caused by three drugs used to model schizophrenia-like symptoms.

    Peptide
    BPC-157
    Outcome
    DecreaseAmphetamine-, apomorphine- and MK-801-induced motor activity effects
    Study

    Ratsn: not reported in source

    Acute motor-activity disturbance induced by amphetamine (3.0), apomorphine (2.5) or MK-801 (0.2)
    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    0.01 mg/kg · Intraperitoneal · Given 5 min before the challengeAs given in this study (Rats).

    Source sentences

    Summary
    Given alone, BPC 157 or L-arginine counteracted the amphetamine-, apomorphine-, and MK-801-induced effect, haloperidol-induced catalepsy and chronic methamphetamine-induced sensitization.
    1 context sentence
    Summary · context
    Medication (mg/kg intraperitoneally) was L-NAME (5), L-arginine (100), BPC 157 (0.01), given alone and/or together, at 5 min before the challenge for the acutely disturbed motor activity (dopamine-indirect/direct agonists (amphetamine (3.0), apomorphine (2.5)), NMDA-receptor non-competitive antagoni…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, BPC‑157 (0.01 mg/kg intraperitoneally) given alone counteracted haloperidol-induced catalepsy.

    In plain wordsIn rats, BPC‑157 reduced catalepsy (a lack of movement) caused by the drug haloperidol.

    Peptide
    BPC-157
    Outcome
    DecreaseHaloperidol-induced catalepsy
    Study

    Ratsn: not reported in source

    Haloperidol-induced catalepsy (haloperidol 2.0)
    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    0.01 mg/kg · Intraperitoneal · Given 5 min before the challengeAs given in this study (Rats).

    Source sentences

    Summary
    Given alone, BPC 157 or L-arginine counteracted the amphetamine-, apomorphine-, and MK-801-induced effect, haloperidol-induced catalepsy and chronic methamphetamine-induced sensitization.
    1 context sentence
    Summary · context
    Medication (mg/kg intraperitoneally) was L-NAME (5), L-arginine (100), BPC 157 (0.01), given alone and/or together, at 5 min before the challenge for the acutely disturbed motor activity (dopamine-indirect/direct agonists (amphetamine (3.0), apomorphine (2.5)), NMDA-receptor non-competitive antagoni…
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, BPC‑157 (0.01 mg/kg intraperitoneally) given alone counteracted chronic methamphetamine-induced sensitization.

    In plain wordsIn rats, BPC‑157 reduced the build-up of drug response that repeated methamphetamine doses cause.

    Peptide
    BPC-157
    Outcome
    DecreaseChronic methamphetamine-induced sensitization
    Study

    Ratsn: not reported in source

    Chronic methamphetamine sensitization (alternating 3 days during the first 3 weeks, challenge after next 4 weeks)
    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    0.01 mg/kg · Intraperitoneal · Given 5 min before the methamphetamine at the second and third weekAs given in this study (Rats).

    Source sentences

    Summary
    Given alone, BPC 157 or L-arginine counteracted the amphetamine-, apomorphine-, and MK-801-induced effect, haloperidol-induced catalepsy and chronic methamphetamine-induced sensitization.
    2 context sentences
    Summary · context
    Medication (mg/kg intraperitoneally) was L-NAME (5), L-arginine (100), BPC 157 (0.01), given alone and/or together,
    Summary · context
    To induce or prevent sensitization, we used chronic methamphetamine administration, alternating 3 days during the first 3 weeks, and challenge after next 4 weeks, and described medication (L-NAME, L-arginine, BPC 157) at 5 min before the methamphetamine at the second and third week.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats given a high dose of L-NAME (40 mg/kg), BPC‑157 (10 μg/kg) given immediately after directly inhibited catalepsy.

    In plain wordsIn rats, BPC‑157 given right after a high dose of L-NAME reduced the catalepsy that L-NAME caused.

    Peptide
    BPC-157
    Outcome
    DecreaseHigh-dose L-NAME-induced catalepsy
    Study

    Ratsn: not reported in source

    Catalepsy induced by a high dose of L-NAME (40 mg/kg intraperitoneally)
    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    10 μg/kg · Intraperitoneal · Given immediately after L-NAMEAs given in this study (Rats).

    Source sentences

    Summary
    Finally, BPC 157 directly inhibits the L-NAME high dose-induced catalepsy.
    1 context sentence
    Summary · context
    Alternatively, BPC 157 10 μg/kg was given immediately after L-NAME 40 mg/kg intraperitoneally.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats, BPC‑157 kept its counteracting effect when nitric oxide synthase was blocked (L-NAME + BPC‑157) or the nitric oxide system was over-stimulated (L-arginine + BPC‑157), unlike L-arginine.

    In plain wordsIn rats, BPC‑157 kept its effect when the nitric oxide system was blocked or over-stimulated, unlike L-arginine.

    Peptide
    BPC-157
    Outcome
    Not applicableBPC 157 effect during NOS blockade or NO over-stimulation
    Study

    Ratsn: not reported in source

    Rat models with NOS blockade (L-NAME) or NO-system over-stimulation (L-arginine)
    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    0.01 mg/kg · Intraperitoneal · Given 5 min before the challengeAs given in this study (Rats).

    Source sentences

    Summary
    Unlike L-arginine, BPC 157 maintains its counteracting effect in the presence of the NOS-blockade (L-NAME + BPC 157) or NO-system-over-stimulation (L-arginine + BPC 157).
    1 context sentence
    Summary · context
    Medication (mg/kg intraperitoneally) was L-NAME (5), L-arginine (100), BPC 157 (0.01), given alone and/or together, at 5 min before the challenge for the acutely disturbed motor activity
  6. 06AnimalAnimal study (in vivo)Mechanism

    In rats, BPC‑157 restored the antagonization that had been abolished by co-administration of L-NAME with L-arginine.

    In plain wordsIn rats, BPC‑157 restored an effect that L-NAME plus L-arginine had removed.

    Peptide
    BPC-157
    Outcome
    Not applicableRestoration of antagonization abolished by L-NAME + L-arginine
    Study

    Ratsn: not reported in source

    Rat models in which L-NAME plus L-arginine abolished the antagonization
    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    0.01 mg/kg · Intraperitoneal · Given 5 min before the challengeAs given in this study (Rats).

    Source sentences

    Summary
    Illustrating the BPC 157-L-arginine relationships, BPC 157 restored the antagonization (L-NAME + L-arginine + BPC 157) when it had been abolished by the co-administration of L-NAME with L-arginine (L-NAME + L-arginine).
    1 context sentence
    Summary · context
    Medication (mg/kg intraperitoneally) was L-NAME (5), L-arginine (100), BPC 157 (0.01), given alone and/or together, at 5 min before the challenge for the acutely disturbed motor activity

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 12:39 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.